These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31709501)

  • 1. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
    Hiramatsu H; Adachi S; Umeda K; Kato I; Eldjerou L; Agostinho AC; Natsume K; Tokushige K; Watanabe Y; Grupp SA
    Int J Hematol; 2020 Feb; 111(2):303-310. PubMed ID: 31709501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
    Maude SL; Laetsch TW; Buechner J; Rives S; Boyer M; Bittencourt H; Bader P; Verneris MR; Stefanski HE; Myers GD; Qayed M; De Moerloose B; Hiramatsu H; Schlis K; Davis KL; Martin PL; Nemecek ER; Yanik GA; Peters C; Baruchel A; Boissel N; Mechinaud F; Balduzzi A; Krueger J; June CH; Levine BL; Wood P; Taran T; Leung M; Mueller KT; Zhang Y; Sen K; Lebwohl D; Pulsipher MA; Grupp SA
    N Engl J Med; 2018 Feb; 378(5):439-448. PubMed ID: 29385370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
    Laetsch TW; Maude SL; Balduzzi A; Rives S; Bittencourt H; Boyer MW; Buechner J; De Moerloose B; Qayed M; Phillips CL; Pulsipher MA; Hiramatsu H; Tiwari R; Grupp SA
    Leukemia; 2022 Jun; 36(6):1508-1515. PubMed ID: 35422096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
    Levine JE; Grupp SA; Pulsipher MA; Dietz AC; Rives S; Myers GD; August KJ; Verneris MR; Buechner J; Laetsch TW; Bittencourt H; Baruchel A; Boyer MW; De Moerloose B; Qayed M; Davies SM; Phillips CL; Driscoll TA; Bader P; Schlis K; Wood PA; Mody R; Yi L; Leung M; Eldjerou LK; June CH; Maude SL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34353848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
    Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.
    Goto H; Makita S; Kato K; Tokushige K; Fujita T; Akashi K; Izutsu K; Teshima T
    Int J Clin Oncol; 2020 Sep; 25(9):1736-1743. PubMed ID: 32448949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
    Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
    Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.
    O'Leary MC; Lu X; Huang Y; Lin X; Mahmood I; Przepiorka D; Gavin D; Lee S; Liu K; George B; Bryan W; Theoret MR; Pazdur R
    Clin Cancer Res; 2019 Feb; 25(4):1142-1146. PubMed ID: 30309857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
    Molinos-Quintana Á; Alonso-Saladrigues A; Herrero B; Caballero-Velázquez T; Galán-Gómez V; Panesso M; Torrebadell M; Delgado-Serrano J; Pérez de Soto C; Faura A; González-Martínez B; Castillo-Robleda A; Diaz-de-Heredia C; Pérez-Martínez A; Pérez-Hurtado JM; Rives S; Pérez-Simón JA
    Front Immunol; 2023; 14():1280580. PubMed ID: 38292483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T cells for sustained remissions in leukemia.
    Maude SL; Frey N; Shaw PA; Aplenc R; Barrett DM; Bunin NJ; Chew A; Gonzalez VE; Zheng Z; Lacey SF; Mahnke YD; Melenhorst JJ; Rheingold SR; Shen A; Teachey DT; Levine BL; June CH; Porter DL; Grupp SA
    N Engl J Med; 2014 Oct; 371(16):1507-17. PubMed ID: 25317870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
    Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
    Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
    Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A
    Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
    Schultz LM; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Rouce RH; Chinnabhandar V; Kunicki M; Barsan VV; Goksenin AY; Li Y; Mavroukakis S; Egeler E; Curran KJ; Mackall CL; Laetsch TW
    J Clin Oncol; 2022 Mar; 40(9):945-955. PubMed ID: 34882493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
    Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
    J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.
    Frey NV; Shaw PA; Hexner EO; Pequignot E; Gill S; Luger SM; Mangan JK; Loren AW; Perl AE; Maude SL; Grupp SA; Shah NN; Gilmore J; Lacey SF; Melenhorst JJ; Levine BL; June CH; Porter DL
    J Clin Oncol; 2020 Feb; 38(5):415-422. PubMed ID: 31815579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
    Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
    Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
    Mueller KT; Maude SL; Porter DL; Frey N; Wood P; Han X; Waldron E; Chakraborty A; Awasthi R; Levine BL; Melenhorst JJ; Grupp SA; June CH; Lacey SF
    Blood; 2017 Nov; 130(21):2317-2325. PubMed ID: 28935694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
    Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
    Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.